Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group
To determine whether combination antibiotic therapy including a short course of an aminoglycoside was as effective and less toxic than a conventional long course of the combination for the empirical therapy of gram-negative bacteremia in patients with cancer and granulocytopenia, we conducted a randomized multicenter trial comparing ceftazidime plus a short course (three days) of amikacin, ceftazidime plus a long course (nine days) of amikacin, and azlocillin plus a long course (nine days) of amikacin. Single-organism gram-negative bacteremia occurred in 129 of 872 evaluable patients. Without a change in antibiotics, the response rates were 81 percent with ceftazidime and long-course amikacin, 48 percent with ceftazidime and short-course amikacin (P = 0.002), and 40 percent with azlocillin and long-course amikacin (P less than 0.001). Among patients with fewer than 100 granulocytes per cubic millimeter throughout therapy, the response rates were 6 percent with ceftazidime and short-course amikacin and 50 percent with ceftazidime and long-course amikacin (P = 0.03). Linear logistic-regression analysis showed that therapy with ceftazidime and long-course amikacin was the most favorable prognostic factor of the response to infection, whereas the presence of leukemia or shock was the least favorable. We conclude that ceftazidime should be given in combination with a conventional full course of an aminoglycoside (amikacin) when used for the empirical treatment of gram-negative bacteremia in cancer patients with granulocytopenia.
This article has been cited by other articles:
Torfoss, D., Hoiby, E. A., Tangen, J. M., Holte, H., Bo, K., Meyer, P., Grottum, K., Weyde, K., Lauritzsen, G. F., Sandstad, B., Jacobsen, A.-B., Olsen, H., Kvaloy, S.
(2007). Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother
59: 711-717
[Abstract][Full Text]
Nichols, W. G.
(2003). Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient. J Intensive Care Med
18: 295-312
[Abstract]
Paul, M., Soares-Weiser, K., Leibovici, L.
(2003). {beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ
326: 1111-
[Abstract][Full Text]
Sanz, M. A., Lopez, J., Lahuerta, J. J., Rovira, M., Batlle, M., Perez, C., Vazquez, L., Julia, A., Palau, J., Gutierrez, M., Capote, F. J., Ramos, F., Benlloch, L., Larrea, L., Jarque, I., for the Spanish PETHEMA Group,
(2002). Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother
50: 79-88
[Abstract][Full Text]
Lynch, J. P. III
(2001). Hospital-Acquired Pneumonia : Risk Factors, Microbiology, and Treatment. Chest
119: 373S-384S
[Abstract][Full Text]
Wiernikowski, J. T., Barr, R. D., Pennie, R.
(2001). Prospective evaluation of a policy of early discontinuation of antibiotics and discharge from hospital in children with cancer who develop fever. J Oncol Pharm Pract
6: 131-137
[Abstract]
Donowitz, G. R., Maki, D. G., Crnich, C. J., Pappas, P. G., Rolston, K. V.I.
(2001). Infections in the Neutropenic Patient-- New Views of an Old Problem. ASH Education Book
2001: 113-139
[Abstract][Full Text]
Giamarellou, H., Bassaris, H. P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E., Zoumbos, N.
(2000). Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrob. Agents Chemother.
44: 3264-3271
[Abstract][Full Text]
Feld, R., DePauw, B., Berman, S., Keating, A., Ho, W.
(2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. JCO
18: 3690-3698
[Abstract][Full Text]
Steyaert, S., Peleman, R., Vaneechoutte, M., De Baere, T., Claeys, G., Verschraegen, G.
(1999). Septicemia in Neutropenic Patients Infected with Clostridium tertium Resistant to Cefepime and Other Expanded-Spectrum Cephalosporins. J. Clin. Microbiol.
37: 3778-3779
[Abstract][Full Text]
Pizzo, P. A.
(1993). Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. NEJM
328: 1323-1332
[Full Text]
Marchbanks, C. R., Rowley, K. A.
(1991). Update on Infections in the Immunocompromised Host. Journal of Pharmacy Practice
4: 282-294
[Abstract]
Previous
